A Study of of MORAb-004 in Subjects With Solid Tumors

Inclusion Criteria:

* Subjects ≥18 years of age.
* Subjects with any malignant solid tumor without intracranial involvement or metastases diagnosed by standard pathology criteria that has failed standard chemotherapy.
* Subject must have disease, as defined by RECIST or evaluable by clinical signs/symptoms (e.g., ascites, pleural effusion, or lesions of less than 2 cm) supported by biomarker, radiologic, or pathologic studies conducted within 4 weeks prior to study entry.
* Karnofsky performance status ≥70%.
* Female subjects of childbearing potential and all male subjects must consent to use a medically acceptable method of contraception throughout the study period and for 30 days after MORAb-004 administration. A barrier method of contraception must be included.
* Laboratory and clinical results within the 2 weeks prior to Study Day 1 as follows: Absolute neutrophil count (ANC) ≥1.5 x 109/L; Platelet count ≥100 x 109/L; Hemoglobin ≥10 g/dL; Serum bilirubin ≤2.0 mg/dL; Aspartate transaminase (AST) ≤2.5 x ULN; or ≤5 x ULN if liver metastases are present; Alanine transaminase (ALT) ≤2.5 x ULN; or ≤5 x ULN if liver metastases are present; Serum creatinine ≤2.0 mg/dL; prothrombin time (PT) and aPTT within institutional limits of normal.
* Subject must be willing and able to provide written informed consent.
* In Part 2 (expansion cohorts) ONLY, subjects must have a histological diagnosis of either CRC or STS (and subtypes, excluding bone sarcomas).

Exclusion Criteria:

* Known central nervous system (CNS) tumor involvement or metastases.
* Evidence of other active malignancy.
* Clinically significant heart disease (e.g., congestive heart failure of New York Heart Association Class III or IV, angina not well controlled by medication, or myocardial infarction within 6 months).
* Electrocardiogram (ECG) demonstrating clinically significant arrhythmias (Note: Subjects with chronic atrial arrhythmia, i.e., atrial fibrillation or paroxysmal SVT, are eligible).
* Presence of severe lung disease (In the absence of clinically apparent severe lung disease, no formal testing is necessary. In the presence of clinically severe lung disease, FEV1 must be \>60% in order for the subject to be eligible.)
* Active serious systemic disease, including active bacterial or fungal infection.
* Chronic inflammatory disorder, e.g., inflammatory bowel disease, active vasculitis.
* Chemotherapy, biologic therapy, or immunotherapy within 3 weeks prior to enrollment.
* Breast-feeding, pregnant, or likely to become pregnant during the study.
* Active hepatitis or human immunodeficiency virus (HIV) infection.
* Subjects who have received a previous monoclonal antibody therapy and have evidence of an immune or allergic reaction, or previously documented human anti-human antibody (HAHA).
* Subjects with large ascites or pleural effusion (≥500 cc) based on results of most recent CT scan).
* Chronic systemic anticoagulation therapy with warfarin or heparin